flow trial semaglutide kidney outcomes The rationale, design and baseline data of FLOW, a with once-weekly in people with type 2 diabetes and chronic kidney disease Contrary to popular belief: GLP-1

SKU: 38523859454

Pay in 4 interest-free payments of $5.99 Learn more

Live Spec

Contrary to popular belief: GLP 1 weight loss medications are NOT all about aesthetic weight loss, they REDUCE risk of cardiovascular death, all cause mortality, and now, progression of kidney disease! Just published semaglutide death Cardiovascular outcomes with by severity of chronic kidney disease in type 2 diabetes The FLOW trial for semaglutide kidney outcomes in T2DM halted due to interim results meeting efficacy criteria FLOW is a RCT comparing injectable semaglutide 1.0 mg with placebo as an adjunct Study: Semaglutide slowed progression of CKD, cut cardiovascular events, mortality risk Media Centre EASD Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double blind placebo controlled clinical trial Nature Medicine

Store: www.allread.ai · Domain: www.allread.ai